ABBV Stock Forecast 2025-2026
Distance to ABBV Price Targets
ABBV Price Momentum
10 Quality Stocks Worth Considering Now
Researching AbbVie (ABBV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ABBV and similar high-potential opportunities.
Latest ABBV Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, ABBV has a bullish consensus with a median price target of $214.00 (ranging from $173.00 to $250.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $201.30, the median forecast implies a 6.3% upside. This outlook is supported by 16 Buy, 10 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Chris Shibutani at Goldman Sachs, suggesting a 14.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABBV Analyst Ratings
ABBV Price Target Range
Latest ABBV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABBV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $240.00 |
| Mar 4, 2025 | B of A Securities | Tim Anderson | Neutral | Maintains | $223.00 |
| Feb 3, 2025 | UBS | Navin Jacob | Neutral | Maintains | $190.00 |
| Feb 3, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $214.00 |
| Feb 3, 2025 | Raymond James | Gary Nachman | Outperform | Reiterates | $220.00 |
| Feb 3, 2025 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $215.00 |
| Feb 3, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $217.00 |
| Feb 3, 2025 | Citigroup | Geoff Meacham | Buy | Maintains | $215.00 |
| Feb 3, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $239.00 |
| Feb 3, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $210.00 |
| Jan 28, 2025 | Citigroup | Geoff Meacham | Buy | Maintains | $205.00 |
| Jan 8, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $211.00 |
| Dec 17, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $220.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Neutral | Reinstates | $191.00 |
| Nov 22, 2024 | Leerink Partners | David Risinger | Outperform | Upgrade | $206.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Outperform | Initiates | $205.00 |
| Nov 13, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $200.00 |
| Nov 12, 2024 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $208.00 |
| Nov 12, 2024 | Citigroup | Geoff Meacham | Buy | Maintains | $215.00 |
| Nov 12, 2024 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $224.00 |
AbbVie Inc. (ABBV) Competitors
The following stocks are similar to AbbVie based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbbVie Inc. (ABBV) Financial Data
AbbVie Inc. has a market capitalization of $356.10B with a P/E ratio of 83.9x. The company generates $56.33B in trailing twelve-month revenue with a 7.6% profit margin.
Revenue growth is +5.6% quarter-over-quarter, while maintaining an operating margin of +36.7% and return on equity of +62.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
AbbVie Inc. (ABBV) Business Model
About AbbVie Inc.
Biopharmaceutical company developing innovative therapies.
AbbVie generates revenue through the research, development, and sale of pharmaceutical products that address serious diseases. Its business model is centered around a strong portfolio of treatments, particularly in autoimmune conditions and oncology, with significant income derived from its flagship product, Humira.
Founded as a spinoff from Abbott Laboratories in 2013, AbbVie has a robust pipeline of new drugs, underpinned by substantial investments in research and development. The company operates in both North America and international markets, emphasizing scientific innovation and high manufacturing standards.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55,000
CEO
Mr. Robert A. Michael CPA
Country
United States
IPO Year
2013
Website
www.abbvie.comAbbVie Inc. (ABBV) Latest News & Analysis
AbbVie Inc. (NYSE: ABBV) is near an all-time high following a licensing agreement with Danish company Gubra for an experimental weight loss drug currently in Phase 1 trials.
AbbVie's licensing deal with Gubra could enhance its pipeline and revenue potential, signaling growth and investor confidence as it approaches an all-time high.
AbbVie (ABBV) closed at $209.17, down 0.4% from the previous trading day.
AbbVie's slight decline in stock price may indicate market sentiment or investor reaction, potentially influencing future trading decisions and overall company valuation.
To receive $1,000 per year in dividends from AbbVie (ABBV), an investor needs to calculate the number of shares based on the current dividend rate.
The excerpt highlights AbbVie as a dividend-paying stock, indicating potential for income generation. Understanding share quantity needed for $1,000 in dividends aids in investment planning.
February investments fell below $1,000, primarily in BDCs, increasing annual dividend income to a record $505, up 5% Y/Y, with a focus on maintaining rising dividends.
Falling investments in BDCs like Owl Rock and Ares may indicate market caution, but rising dividend income signals robust performance and potential for continued income growth.
2025 Dividend Kings: Strong Run Continues
6 days agoIn 2025, Dividend Kings are outperforming the S&P 500 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%).
The outperformance of Dividend Kings signals strong investment stability and potential for returns, highlighting attractive opportunities in these stocks compared to broader indices.
Prescription medicines may be affected by tariffs from the Trump administration and potential EU retaliatory measures, impacting their availability and pricing.
Tariffs on prescription medicines may increase costs for pharmaceutical companies, impacting profit margins and stock prices, while potential EU retaliation could disrupt market access.
Frequently Asked Questions About ABBV Stock
What is AbbVie Inc.'s (ABBV) stock forecast for 2025?
Based on our analysis of 39 Wall Street analysts, AbbVie Inc. (ABBV) has a median price target of $214.00. The highest price target is $250.00 and the lowest is $173.00.
Is ABBV stock a good investment in 2025?
According to current analyst ratings, ABBV has 16 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $201.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABBV stock?
Wall Street analysts predict ABBV stock could reach $214.00 in the next 12 months. This represents a 6.3% increase from the current price of $201.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbbVie Inc.'s business model?
AbbVie generates revenue through the research, development, and sale of pharmaceutical products that address serious diseases. Its business model is centered around a strong portfolio of treatments, particularly in autoimmune conditions and oncology, with significant income derived from its flagship product, Humira.
What is the highest forecasted price for ABBV AbbVie Inc.?
The highest price target for ABBV is $250.00 from at , which represents a 24.2% increase from the current price of $201.30.
What is the lowest forecasted price for ABBV AbbVie Inc.?
The lowest price target for ABBV is $173.00 from Chris Shibutani at Goldman Sachs, which represents a -14.1% decrease from the current price of $201.30.
What is the overall ABBV consensus from analysts for AbbVie Inc.?
The overall analyst consensus for ABBV is bullish. Out of 39 Wall Street analysts, 16 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $214.00.
How accurate are ABBV stock price projections?
Stock price projections, including those for AbbVie Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
